PA-451
PA-451 is a novel investigational drug currently under research for its potential therapeutic effects in treating Type 2 Diabetes Mellitus. It is classified as a small molecule inhibitor targeting specific pathways involved in glucose metabolism and insulin sensitivity.
Mechanism of Action[edit | edit source]
PA-451 functions by inhibiting the activity of a specific enzyme involved in the regulation of glucose homeostasis. This enzyme, which is overactive in patients with Type 2 Diabetes Mellitus, contributes to increased blood glucose levels and insulin resistance. By inhibiting this enzyme, PA-451 helps to restore normal glucose levels and improve insulin sensitivity.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of PA-451 includes its absorption, distribution, metabolism, and excretion characteristics. PA-451 is administered orally and has a high bioavailability. It is extensively metabolized in the liver, primarily through the cytochrome P450 enzyme system, and is excreted mainly via the renal route.
Clinical Trials[edit | edit source]
PA-451 is currently undergoing Phase II clinical trials to evaluate its efficacy and safety in patients with Type 2 Diabetes Mellitus. Preliminary results have shown promising outcomes in terms of reducing HbA1c levels and improving fasting blood glucose levels.
Adverse Effects[edit | edit source]
The most common adverse effects reported in clinical trials include mild gastrointestinal disturbances, such as nausea and diarrhea. No serious adverse effects have been reported thus far, but long-term safety data is still being collected.
Regulatory Status[edit | edit source]
As of the latest update, PA-451 has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational drug.
Research and Development[edit | edit source]
PA-451 was developed by a collaboration between academic researchers and a pharmaceutical company. The research focuses on targeting novel pathways in diabetes management, aiming to provide an alternative to existing therapies.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
